Semperit Ag Holding · VIE:SEM

Semperit — FY2016 Earnings Presentation

23 slides from Semperit's earnings presentation, Mar 10, 2017

  1. Slide 1: Semperit Group Investor Presentation FY 2016

    SEMPERIT GROUP INVESTOR PRESENTATION FY 2016 Thomas Fahnemann, CEO Frank Gumbinger, CFO 10 March 2017 1

  2. Slide 2: Agenda

    Agenda Operational Development and Financial Performance Outlook Appendix 2 Investor Presentation FY 2016 I 10 March 2017 I Investor Relations

  3. Slide 3: Financial Year 2016 impacted by weak markets and one-off effects

    Financial Year 2016 impacted by weak markets and one-off effects Revenue by segment 2016 (vs. 20152)) Sound Industrial Sector offset by weak Medical Sector Sempermed Semperflex 41% (43%) 24% (22%)  Industrial Sector with volume growth and further gains in market share despite very difficult markets

  4. Slide 4: Semperflex: Excellent performance; Sempertrans: Competing successfully

    Semperflex: Excellent performance Sempertrans: Competing successfully in very challenging markets FY 2016 vs. FY 20151) Revenue -0.5%  Good utilisation due to strategic alliances with key customers despite challenging Semperflex EBITDA +4% market environment  Hydraulic hoses: Outperforming the EBI

  5. Slide 5: Semperform: Stable development; Sempermed: Negative effects

    Semperform: Stable development Sempermed: Negative effects from margin squeeze and one-off items FY 2016 vs. FY 20151) +2%  Market share gains in decreasing markets Revenue Semperform  Profiles: successful market entry in the EBITDA 2) +5% USA; increasing market share in Western and Central Europe

  6. Slide 6: Highlights of agreed Joint Venture transaction

    Highlights of agreed Joint Venture transaction Semperit Sri Trang Highlights 100% Siam Sempermed 100% Sempermed USA, USA Corporation (SSC), Thailand  Approximately USD 200m cash inflow before tax Sempermed 100% Sempermed Singapore, Singapore  USD 167.5m compensation payment to 100% 76% Semperit Fo

  7. Slide 7: Challenging market conditions in all sectors

    Challenging market conditions in all sectors Revenue by segment 2016 vs. 2015 in EUR m -6.8% 914.7 -1.0 -16.5 +3.0 -47.7 852.4 Industrial Sector Medical Sector -2.8% -0.5% -10.0% +1.9% -12.1% FY 2015 Semperflex Sempertrans Semperform Sempermed FY 2016 -0.5% = % change 7 Investor Presentation FY 2016

  8. Slide 8: EBIT mainly impacted by one-off effects

    EBIT mainly impacted by one-off effects EBIT by segment 2016 vs. 20151) in EUR m -59.1% 66.7 +1.3 -7.8 -0.8 -41.2 SSC -8.7 49.0 effect SSC 7.9 effect -21.7 one-offs +21.7 27.3 13.8% 7.3% -10.8 +9.0 41.1 5.8% 3.2% 19.5% 8.2% 11.8% -6.9% EBIT Semperflex Sempertrans Semperform Sempermed Corporate EBIT

  9. Slide 9: 2016 one-off effects related to the planned JV termination

    2016 one-off effects related to the planned JV termination Total one-off effects Negative effects in 2016 more than offset in 2017 in EUR m 85-951) 2016: Value adjustments related to planned JV termination and weak Sempermed performance  Impairment of Sempermed Goodwill (-17.0m)  Tax accruals Braz

  10. Slide 10: Dividend Payment linked to closing of JV transaction

    Dividend Payment linked to closing of JV transaction  Management Board will propose a dividend of EUR 0.70 per share for FY 2016 to the AGM  Adjusted earnings per share (without one-off effects) of EUR 1.12 per share for FY 2016  Dividend proposal is based on the assumption that there will be a c

  11. Slide 11: 2016: Solid results before one-off effects despite weak markets

    2016: Solid results before one-off effects despite weak markets Key Financials Semperit Group in EUR m 2016 20151) % Revenue 852.4 914.7 -6.8% Adj. EBITDA2) 82.6 96.2 -14.1% EBITDA 77.9 96.2 -19.0% Adj. EBIT2) 49.0 66.7 -26.5% EBIT 27.3 66.7 -59.1 % Adj. Earnings after tax2) 23.1 46.4 -50.1% Earning

  12. Slide 12: CAPEX and Working Capital Overview

    CAPEX and Working Capital Overview CAPEX per Segment Components of Working Capital in EUR m in EUR m -9.4% -9.5% 71.8 160.6 145.4 65.1 14.6 14.4 Semperflex 135.7 138.1 Inventories 12.3 6.7 Sempertrans 8.1 13.8 Semperform 125.5 118.8 Trade receivables 29.6 25.7 Sempermed -100.7 -111.6 Trade payables

  13. Slide 13: Agenda

    Agenda Operational Development and Financial Performance Outlook Appendix 13 Investor Presentation FY 2016 I 10 March 2017 I Investor Relations

  14. Slide 14: Outlook 2017: Positive effects from JV transaction expected

    Outlook 2017: Positive effects from JV transaction expected Semperit outlook  Stable sales development with high capacity utilisation  Results of 2017 will be driven by significant positive effects (EUR 85-95m EBIT effect) of JV transaction  Adjusted EBIT 2017 before one-offs below 2016 figure (E

  15. Slide 15: Contact and financial calendar

    Contact and financial calendar Investor Relations Semperit Group Financial Calendar 2017 Stefan Marin, Head of Investor Relations 10/03/2017 Publication of 2016 annual +43 1 79777 - 210 financial statements www.semperitgroup.com/en/ir 16/05/2017 Report on Q1 2017 Modecenterstrasse 22 23/05/2017 Annu

  16. Slide 16: Agenda

    Agenda Operational Development and Financial Performance Outlook Appendix 16 Investor Presentation FY 2016 I 10 March 2017 I Investor Relations

  17. Slide 17: Sharp increase in raw material prices since November 2016

    Sharp increase in raw material prices since November 2016 Prices for important raw materials rose quickly by 50-100% in the last 4 months Styrene Butadiene Rubber 15021) Natural Latex 60% MRB in MYRc/kg 225 900 200 800 175 700 150 600 125 500 100 400 75 300 50 SBR Europe SBR Asia 1) Index based on 0

  18. Slide 18: Group and Sectors: 2016 vs. 2015

    Group and Sectors: 2016 vs. 2015 Industrial Sector Medical Sector Semperit Group1) 2015 2015 2015 In EUR m 2016 % 2016 % 2016 % restated2) restated2) restated2) Revenue 506.4 521.0 -2.8% 346.0 393.7 -12.1% 852.4 914.7 -6.8% Adjusted EBITDA 11.2 29.4 -61.5% 82.6 96.2 -14.1% Adjusted EBITDA margin 3.3

  19. Slide 19: Semperit Group per quarter

    Semperit Group per quarter Key Financials Semperit Group1) FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Adj. in EUR m 2014 2015 2015 2015 2015 2015 2016 2016 2016 2016 2016 2016 Revenue 858.3 217.5 233.4 241.3 222.6 914.7 219.5 219.2 208.9 204.8 852.4 EBITDA 101.9 21.8 28.5 25.1 20.8 96.2 26.7 26.1 19.4 5.7 77.

  20. Slide 20: Semperflex and Sempertrans per quarter

    Semperflex and Sempertrans per quarter Key Financials Semperflex1) in EUR m FY 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 FY 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 FY 2016 Revenue 202.1 55.4 52.5 48.3 47.1 203.4 52.8 53.6 47.2 48.8 202.3 EBITDA 48.5 13.6 13.3 11.0 8.3 46.1 13.3 13.9 9.8 11.1 48.0 EBITDA 24.

  21. Slide 21: Semperform and Sempermed per quarter

    Semperform and Sempermed per quarter Key Financials Semperform1) in EUR m FY 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 FY 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 FY 2016 Revenue 129.0 31.8 41.7 44.0 35.3 152.8 38.2 42.8 40.5 34.2 155.7 EBITDA 18.6 3.7 10.1 7.3 3.2 24.3 6.0 7.7 6.7 5.3 25.6 EBITDA 14.5% 11.6

  22. Slide 22: Solid balance sheet structure and financial flexibility

    Solid balance sheet structure and financial flexibility Balance sheet structure 31 December 2016 Financial profile as of 31 December 2016 Balance sheet total: EUR 1,035 m  Cash and cash equivalents of EUR 190m despite investment programme Assets for Sale Other liabilities 153 164 incl. deferred tax

  23. Slide 23: Key figures 2008 – 2016

    Key figures 2008 – 2016 Key performance figures Adj. in EUR m 2008 2009) 20101) 20111) 2012 2013 20143) 20153) 2016 2016 Revenue 655.3 588.1 689.4 820.0 828.6 906.3 858.3 914.7 852.4 EBITDA 87.9 102.8 112.3 110.0 108.7 132.5 101.9 96.2 77.9 82.6 EBITDA margin 13.4% 17.5% 16.3% 13.4% 13.1% 14.6% 11.9

Semperit AG Holding — FY2016 Earnings Presentation on 6ix